Oxacillin for Injection — Class II drug recall D-0936-2023
Ongoing recall by Sagent Pharmaceuticals, reported 2023-08-02, distributed nationwide. Lack of Assurance of Sterility
| Recall number | D-0936-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Sagent Pharmaceuticals, Schaumburg, IL, United States |
| Recall initiated | 2023-07-11 |
| Classified | 2023-07-21 |
| Reported by FDA | 2023-08-02 |
| Distributed | Nationwide (US) |
| Quantity | 65,710 vials |
| Reason classes | sterility |
| NDC | 25021-0162-24, 25021-0162-68 |
| Expiration dates | 2025-05-31, 2025-06-30, 2025-11-30, 2025-12-31 |
Product
Oxacillin for Injection, USP, 2 grams per vial, For IV or IM Use, Rx only, labeled as a) NDC 25021-162-24 and b) novaplus NDC 25021-162-68, Mfd. for SAGENT Pharmaceuticals, Schaumburg, IL 60195. Made in India.
Reason for recall
Lack of Assurance of Sterility
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0936-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.